Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Abstract: Compositions and methods for providing desired cannabinoid content in cannabis plants. More particularly, the invention relates to compositions and methods for using cannabinoid synthase paralogs as guidance for breeding cannabis plants with a desired cannabinoid content, including but not limited to cultivars, varieties, lines and methods of breeding the same for commercial use.

Abstract: A method of early detection of scaling on internal surfaces of conduits of water processing equipment, is provided herein. The method includes: transmitting ultrasonic signals through the wall of the conduits; deriving data samples from received ultrasonic signals or reflections thereof; calculating a moving average of the scatter of the ultrasonic signals, over time, based on the data samples; applying a statistical operand to the moving average, to yield a statistical distribution metric; determining a dynamic window defined by: (i) an upper boundary being the moving average plus at least a fraction of the statistical distribution metric and (ii) a lower boundary being the moving average minus the at least a fraction of the statistical distribution metric; generating a trend line being a smooth fitting of the derived samples; and monitoring the trend line within the window to detect a crossover of the trend line at either of the boundaries.

Abstract: The present invention includes a composition comprising an A2A agonist. The present invention also includes a method of treating or reducing the symptoms of a neuroinflammatory disease in a patient in need thereof, wherein the method comprises administering to the patient a therapeutically effective amount of an A2A agonist. In one embodiment, the A2A agonist is administered intrathecally to the patient. In another embodiment, the A2A agonist comprises ATL313.

Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.

Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.